Precision Onco Ltd 4
4 · CONSTELLATION PHARMACEUTICALS INC · Filed Jul 23, 2018
Insider Transaction Report
Form 4
Precision Onco Ltd
10% Owner
Transactions
- Conversion
Series F Preferred Stock
2018-07-23−3,500,000→ 0 total→ Common Stock (317,921 underlying) - Conversion
Common Stock
2018-07-23+317,921→ 317,921 total
Footnotes (1)
- [F1]On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.